We are live on
!
Find out more
MCM
Marathon Capital Management Portfolio holdings
AUM
$445M
1-Year Est. Return
26.09%
This Fund
S&P 500
This Quarter
Est. Return
+11.7%
1 Year Est. Return
+26.09%
3 Year Est. Return
+49.93%
5 Year Est. Return
+48.4%
10 Year Est. Return
+349.58%
AUM
$437M
AUM Growth
+$44.4M
(+11%)
Cap. Flow
+$7.6M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
39.84%
Holding
178
New
15
Increased
34
Reduced
73
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$7.74M |
| 2 |
Adobe
ADBE
|
+$4.47M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$3.36M |
| 4 |
ADMA Biologics
ADMA
|
+$3.13M |
| 5 |
PAR Technology
PAR
|
+$2.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Symbotic
SYM
|
+$3.37M |
| 2 |
T. Rowe Price
TROW
|
+$2.47M |
| 3 |
Pfizer
PFE
|
+$2.04M |
| 4 |
Corning
GLW
|
+$1.04M |
| 5 |
Calix
CALX
|
+$946K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.76% |
| 2 | Technology | 21.1% |
| 3 | Healthcare | 12.26% |
| 4 | Industrials | 10.95% |
| 5 | Energy | 7.1% |
Similar funds
RWM
WC
NAMP
BI
MLIC
JDLA
GC
SCA
Marathon Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Marathon Capital Management held 178 positions worth $437M, up 11% from $393M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Marathon Capital Management's Q3 2025 filing shows 15 new, 34 increased, 73 reduced and 15 closed positions. Its largest new stake was Adobe: 12,457 shares worth $4.39M. The largest sale was Symbotic, an estimated $3.37M.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- Marathon Capital Management's largest Q3 2025 buy was Adobe: 12,457 shares worth $4.39M.
- Marathon Capital Management added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q3 2025, an estimated $7.74M increase.
- Marathon Capital Management's biggest Q3 2025 reduction was Symbotic, cutting an estimated $3.37M.
- Marathon Capital Management fully exited Sarepta Therapeutics in Q3 2025, selling an estimated $711K.
- Marathon Capital Management's ten largest holdings make up 40% of its $437M portfolio in Q3 2025.
- Marathon Capital Management opened 15 new positions and closed 15 in Q3 2025.
- Marathon Capital Management's portfolio value rose 11% quarter-over-quarter to $437M.
Based on Marathon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.